Newsletter · 2026-07-24 · Ashutosh Agarwal

Lilly and Novo Escalate Obesity War as Biotech Rallies Back - Healthcare Podcast Weekly Digest - Week of July 24, 2026

Healthcare podcast synthesis for the week of July 18–24, 2026. Eli Lilly's mixed retatrutide data and Novo Nordisk's false-advertising lawsuit intensified the obesity-drug war, UnitedHealth's blowout quarter reversed a year of managed-care gloom, and a wave of M&A capped one of biotech's best years in memory.

Healthcare Podcast Weekly Digest

Week of July 24, 2026: Lilly and Novo Escalate Obesity War as Biotech Rallies Back

Opening Summary

This was a week defined by one enormous rivalry and one enormous recovery.

The rivalry is the obesity-drug war between Eli Lilly and Novo Nordisk, and this week it got louder on every front, in the clinic, in the courtroom, and in the ad break. Lilly reported the first big data from its next-generation "triple-hormone" shot, retatrutide, and the read was genuinely mixed: strong weight loss, but a cardiovascular result that fell short and a filing that just slipped into 2027. Novo, meanwhile, sued Lilly over its advertising. On the podcasts, clinicians and commentators kept coming back to the same question: does the "biggest number wins" marketing war actually help patients, or just move product?

The recovery is in biotech, which has quietly had one of its best years in memory. On CNBC's Power Lunch (July 23, 2026), BMO's head of healthcare research called it "a year to remember," and the mood across the biotech podcasts was that the money is flowing back in, through a wave of takeovers of smaller, de-risked drugmakers and a re-opening market for new listings.

Alongside those two stories: UnitedHealth delivered a blowout quarter that flipped a year of gloom into a wall of analyst upgrades; a 100% tariff on imported generic drugs landed as a new policy overhang; psychedelics got a $2.8 billion stamp of approval from Lilly; and artificial intelligence in drug discovery kept generating eye-catching numbers and equally loud skepticism.

Here is what the people on the podcasts, and in the news, were actually saying.

Key People This Week

Hot Topics

Eli Lilly vs. Novo Nordisk: the obesity war on three fronts

This was the dominant theme of the week, appearing in more than a dozen podcasts.

The clinical front: retatrutide's mixed debut. On July 23, Lilly released the first Phase 3 data on retatrutide, its next-generation shot that hits three gut hormones at once (GLP-1 plus glucagon plus GIP) instead of one or two. Bloomberg Intelligence explained why people care: it "combines three different gut hormones... basically, it just supercharges the drug a little bit... maybe better for things like removing fat from the liver," and is aimed at "people that need that higher degree of weight loss" who don't succeed on today's drugs (Bloomberg Intelligence, July 23, 2026).

The results themselves were a genuine "yes, but":

• In TRIUMPH-2 (people with type 2 diabetes and obesity), the top 12 mg dose produced about 20.8% average weight loss at 80 weeks versus 3.2% for placebo (fiercebiotech.com). In pounds, the three doses delivered roughly 29.8, 45.4 and 49.6 lbs of weight loss (thefly, July 23, 2026).
• In TRIUMPH-3 (severe obesity plus established heart disease), the 12 mg dose drove 22.6% weight loss, up to about 55.8 lbs (biospace.com; thefly).
• But those figures came in below the ~28% weight loss seen in Lilly's earlier retatrutide trials, because sicker, diabetic patients tend to lose less (fiercebiotech.com).
• The bigger disappointment: the heart-attack-and-stroke benefit did not reach statistical significance (27 events in the drug group versus 23 on placebo), which Lilly blamed on an unusually low event rate (biopharmadive.com).
• As a result, Lilly pushed its FDA filing from late 2026 to the first quarter of 2027 to gather more manufacturing data (biopharmadive.com; thefly).

In plain terms: retatrutide clearly works for weight loss, but this particular data set didn't give the clean "it also protects your heart" headline the market wanted, and approval is now a 2027 story.

The courtroom front: Novo sues Lilly. On July 21, Novo Nordisk sued Eli Lilly in federal court in New Jersey, alleging Lilly's direct-to-consumer ads for Zepbound and Mounjaro violate false-advertising and unfair-competition law, including the Lanham Act (thefly, July 21, 2026; forbes.com). Novo's core complaint: Lilly compares the maximum dose of its drug against the lowest dose of Novo's, ignoring newer data where the higher 7.2 mg dose of Wegovy produced about a 47-pound weight loss, essentially neck-and-neck with Zepbound (washingtonpost.com). Novo wants the ads pulled and a corrective campaign run.

On The Rundown (July 22, 2026), the host read it as a competitor lashing out after losing its lead: "Novo Nordisk had the lead... but then Eli Lilly came out with Zepbound and Mounjaro, which were better, and they took the market... Eli Lilly stock has gone up 50% in the last 12 months, while Novo Nordisk has lost 24%... now they're hitting the lawsuit button in hopes of slowing down Lilly." Lilly's defense, echoed everywhere, is that head-to-head trials like SURMOUNT-5 are the "gold standard," and no such trial yet exists for Novo's newest doses.

The clinician's view: a pox on both houses. The most thoughtful take came from On The Pen (July 22, 2026), which argued the marketing war misses the point. Tirzepatide (Lilly) beat semaglutide (Novo) in the SURMOUNT-5 trial and, the host said, in real life too, but the deeper truth is that obesity "is not one disease... it is many," and "the idea that there's a universal winner just by hitting a higher number has always been overly simplistic." The verdict: "what we see here is pharma battling again over the patient, but not necessarily for the patient."

The pill race. Several podcasts flagged that the fight is moving from injections to pills. Novo's oral Wegovy just became the first oral GLP-1 approved for weight management in Europe, while Lilly's new obesity pill, Foundayo (orforglipron), is off to a slower start. On Everyone Talks To Liz Claman (July 18, 2026), eMed CEO Linda Yaccarino said Lilly's pill was capturing only about 11% of new GLP-1 pill prescriptions against Novo's dominance. BioSpace (July 22, 2026) said Lilly's upcoming quarter will give the first real sales numbers for Foundayo, and it is "the most watched" print in the group.

UnitedHealth: from disaster to darling

UnitedHealth Group's July 16 quarter was the managed-care story of the week. After a brutal year, the company posted adjusted earnings of $6.38 a share, crushing the $4.92 expected, on revenue of $112.0 billion (thefly, July 16, 2026). More importantly, it raised full-year guidance to $19.50–$20.00 per share, up from "over $18.25."

The number analysts fixated on was the medical care ratio (the share of premium dollars paid out as medical claims, where lower means more profit). It improved to 86.7%, a 270-basis-point (2.7 percentage point) improvement from a year earlier, helped by $860 million of favorable prior-period claims (unitedhealthgroup.com). The one blemish: management flagged commercial medical costs running modestly above 11%, which is why the stock gave back much of its early pop.

On Money Tree Investing (July 22, 2026), co-host Doug used UNH as a case study in buying a beaten-down leader, leaning on insider purchases as his tell: "when you see a pattern of multiple insiders executing purchases on a stock, especially after a stock may have pulled back, it can be an indicator." He noted the stock has since staged "a tremendous rally."

Biotech's comeback and the robots

Biotech was the week's feel-good story. On Power Lunch (July 23, 2026), BMO's Evan Siegerman said the two main biotech ETFs had "surged significantly over the last year" and that there's still room to run "if you pick the right stocks," favoring names "set up best for M&A."

In medical devices, Intuitive Surgical's Kate Nowlan laid out the scale of the robotic-surgery franchise on Medtech Talk (July 21, 2026): more than 10,000 instruments in the field, 100,000 trained surgeons, and 20 million procedures generating the data now powering new AI tools. A Mayo Clinic panelist described adoption spreading well beyond the operating room, into OB-GYN, urology, even the pharmacy and lab.

Key Debates

Retatrutide: game-changer or over-hyped?

• Bull: It is the most powerful weight-loss drug yet, targeting patients who fail on current options and offering liver and metabolic benefits. Bloomberg Intelligence framed it as the natural next step "for people that need that higher degree of weight loss."
• Bear: This week's specific data disappointed: weight loss came in below Lilly's own earlier trials, the heart-protection benefit wasn't statistically proven, and the filing slipped to Q1 2027. The "supercharged" narrative met a messier reality.

Lilly vs. Novo: is the marketing fight meaningful?

• Bull (Lilly): Head-to-head trials are the gold standard, Lilly won them, and its stock is up ~50% over 12 months for a reason (The Rundown, July 22).
• Bear (Novo / clinicians): Comparing your best dose to a rival's weakest dose is misleading, and Novo's newest 7.2 mg Wegovy closes the gap to ~47 lbs (washingtonpost.com). Clinicians on On The Pen argue the "biggest number" framing is bad medicine regardless of who wins.

UnitedHealth: real recovery or one good quarter?

• Bull: A 31% earnings beat, a 12% guidance raise, and a sharply better medical care ratio triggered near-universal price-target hikes: Morgan Stanley to $529, Wells Fargo to $526, JPMorgan to $516 (thefly, July 17–21). Baird went further and upgraded the stock outright.
• Bear: Baird still flags "structural risks across Optum Health and Optum Insight," and commercial medical costs running above 11% are a live worry, enough that the stock gave back most of its early gains and dragged read-throughs to Cigna and Elevance lower (thefly / RBC, July 17).

Does "shareholder-first" break healthcare?

Eric Ries argued on The Heart of Healthcare (July 20) that Novo's foundation-controlled structure saved the company billions by preventing a short-sighted merger, a provocative case that patient-mission governance can beat pure profit-maximization even on profit. The counter, which he acknowledges investors reflexively make: don't complicate the ownership structure.

Emerging Themes

AI in drug discovery: big claims, loud skeptics. This was a recurring thread. On StrictlyVC (July 21, 2026), Reid Hoffman offered the optimistic case with hard numbers: AI-designed "synthetic control arms" can halve patient recruitment for a $260 million Phase 3 trial, and Revolution Medicines reached a $40 billion valuation by using AI to hit KRAS, a target "undruggable for 50-60 years." The Digital Pathology Podcast (July 22) added the money trail: Roche bought PathAI for about $1 billion, and Alphabet's Isomorphic Labs raised $2.4 billion. But the same episode, and Data in Biotech (July 20), pushed back hard, chemist Woody Sherman argued language models "fail for drug discovery" because molecules need "physical AI," not text prediction. The theme: enormous capital, real early wins, and genuine debate over whether the hype is ahead of the science.

Psychedelics get de-risked. Big Pharma is now buying in. Lilly's $2.8 billion (up to ~$3.8 billion with milestones) purchase of AtaiBeckley for a 5-MeO-DMT depression drug (thefly, July 16) was called by H.C. Wainwright "the clearest strategic validation to date of psychedelics... as an emerging pharmaceutical category" (BioSpace, July 22). It follows AbbVie's $1.2 billion Gilgamesh deal and Otsuka's $1.2 billion Transcend deal, a pattern analysts say shows the space is now mainstream enough for the majors.

GLP-1s as more than weight-loss drugs. Across several clinical podcasts, the story widened: on Itchy & Bitchy (July 20), cardiologist Dr. Stephen Miller cited a 14% drop in major cardiovascular events and a 24% improvement in kidney outcomes; Power Lunch noted Lilly's tirzepatide got "spectacular results in psoriasis." The investment implication, raised on Power Lunch: if GLP-1s treat inflammation broadly, they could eventually threaten drugs in categories nobody currently thinks of as competitors.

Alignment on transparent PBMs. A cluster of pharmacy podcasts (The Benefits Playbook, The Astonishing Healthcare Podcast, both July 17–23) featured challenger pharmacy-benefit managers pushing "transparency" against incumbents CVS, Cigna and UnitedHealth, a slow-burning structural pressure on the big managed-care middlemen.

Deals & M&A Tracker

The broader read across the biotech podcasts: takeovers of small, de-risked, late-stage drugmakers are accelerating, and the new-listing (IPO) market is reopening for the back half of 2026 (BioSpace, July 22).

Regulatory Watch

• 100% tariff on imported generic drugs (July 21–22). President Trump proposed a tariff "cliff" on imported generic drugs: 0% for two years from August 1, 2026, then 100% in 2028 and 200% in 2029, explicitly to force manufacturing back to the U.S. (thefly, July 21; pharmexec.com). Crucially, patented and branded drugs are exempt. The pain lands on generic supply chains (Indian drugmakers supply nearly half of U.S. generics, and generics are 90% of prescriptions filled), so analysts warn of drug shortages and discontinuations rather than simple price hikes (pharmexec.com; ajmc.com). Lilly was named on the list, but as a branded innovator it is largely shielded.
• FDA compounding advisory committee (July 23–24). The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for compounding approval, a make-or-break event for telehealth players like Hims & Hers (HIMS) pushing into the peptide space (investing.com).
• FDA / DOJ crackdown on GLP-1 telehealth and compounding. On FDA Watch (July 20), lawyers detailed a widening enforcement push: warning letters (including one to Novo Nordisk on drug-safety monitoring), a proposed rule to bar semaglutide and tirzepatide from the bulk-compounding list (which would strip large compounders of their ability to make copycat GLP-1s), and a $600 million settlement with Alibaba's payment arm over roughly 80,000 U.S. transactions in illegal pharmaceuticals. On The Pen (July 22) also flagged a STAT News investigation into publicly traded telehealth firm LifeMD's prescribing practices (which the company strongly denies).
• DOJ antitrust probe touches the insurers (July 14). The Justice Department expanded an antitrust investigation into Claritev over allegations it helped insurers including UnitedHealth, CVS's Aetna and Cigna coordinate to cut out-of-network reimbursement; Claritev shares fell 10% (thefly / Bloomberg, July 14).
• Lilly's Retevmo wins full FDA approval (July 14) for RET fusion-positive solid tumors, converting an earlier accelerated approval to traditional approval (FDA, July 14).
• Alzheimer's setback. Biogen and Ionis' tau-targeting drug missed its main goal on dose-response, though it showed 26% slowing on one cognitive measure at the lowest dose; Biogen is pushing to Phase 3 anyway, and "investors were unhappy" (BioCentury This Week, July 21; Biotech Hangout, July 17).

Week Ahead

• The big earnings wave in obesity and pharma. Eli Lilly and Novo Nordisk report in the coming weeks, the single most-watched prints in healthcare. Investors want Lilly's continued Mounjaro/Zepbound growth and the first real sales figures for the Foundayo pill; for Novo, BMO thinks a possible guidance upgrade "might help sentiment" (Power Lunch, July 23; BioSpace, July 22).
• Bristol-Myers Squibb reports next week, kicking off big-pharma earnings; watch Merck (BMO's preferred name, $142 target) and AbbVie ($300 target) in the following weeks (Power Lunch, July 23).
• Roivant's brepacitinib carries a September FDA decision (PDUFA) date and launch for dermatomyositis, modeled as a potential $6–12 billion drug, with uveitis Phase 3 data due by year-end (Biotech Hangout, July 17).
• The Lilly-Novo lawsuit now enters the legal process; any early ruling on whether Lilly must pull or correct its ads is a live catalyst for both stocks.
• Tariff clock. The generic-drug tariff transition period begins August 1, 2026; expect continued positioning in generic and supply-chain names even though the 100% rate is two years out.
• More retatrutide detail is expected at a future medical meeting, where fuller cardiovascular and safety data could reframe this week's mixed reception ahead of the Q1 2027 filing.